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One-quarter of pediatric pre-B-cell leukemias contain the t(1;19) chromosomal translocation, which fuses 5'
exons encoding the transactivation domain of the E2A transcription factor gene to 3' exons encoding the
putative DNA-binding region of the unusual homeobox gene, PBX1. To test the leukemic potential of this fused
gene, a cDNA encoding its major protein product, p85E2A-Pbx, was incorporated into a retrovirus construct
and introduced into normal mouse marrow progenitors by infection. The cells were used in a bone marrow
transplantation protocol to reconstitute the hematopoietic compartments of lethally irradiated recipients. After
3 to 8 months, reconstituted mice developed acute myeloid leukemias that expressed high levels of p85ooA-Pxl
and were readily transmissible to immunocompetent mice. Most acute myeloid leukemias also grew as
granulocytic sarcomas and exhibited some neutrophilic differentiation. These results demonstrate a causative
role for p85E2A-rbxl in human acute leukemia and indicate that the oncogenic potential of Pbxl is not limited
to pre-B-cell malignancies.
The t(1;19)(q23;pl3.3) chromosomal translocation is found
in the leukemic blasts of 25% of children with pre-B-cell
acute lymphoblastic leukemia (pre-B ALL) (3, 23). In more
than 90% of cases (19), the translocation breakpoint occurs
within the same introns of the E2A and PBX1 genes, joining
exons of E2A that encode a transcriptional transactivator
domain (9) to exons of PBX1 that encode a putative DNA-
binding, homeobox domain (Fig. 1) (12, 17), and producing a
family of five E2A-Pbxl fusion proteins (11, 19). Differential
splicing, which affects the carboxyl terminus of Pbxl, ac-
counts for the expression of two major E2A-Pbxl fusion
proteins, designated p85E2A-Pbxl and p77E2A-Pbx1 (12).
The oncogenicity of E2A-Pbxl proteins has been tested
thus far in NIH 3T3 fibroblasts. When assayed by focus
formation, growth in agar, or contact inhibition in NIH 3T3
cells, the transforming activity of p85E2APbxl is poor and
that of p77E2A-Pbxl is moderate. However, NIH 3T3 cells
expressing either p85E2APbxl or p77E2A-Pbxl form tumors in
nude mice (11), indicating that both proteins have malignant
potential. Although NIH 3T3 transformation assays indicate
that E2A-Pbxl proteins are oncogenic, direct induction of
acute leukemia, particularly of the B-cell lineage, in mice
would be the strongest argument that expression of E2A-
Pbxl causes or contributes to the formation of human pre-B
ALL containing t(1;19).
To determine the effects of human E2A-Pbxl proteins on
blood cell differentiation, we introduced the major form of
E2A-Pbxl, p85E2A-Pbx1, into normal mouse marrow cells by
infection with a helper-free E2A-Pbxl recombinant retrovi-
rus (11). Infection of marrow progenitors with E2A-Pbxl
virus did not alter their growth properties in vitro, even
when conditions favoring the growth of pre-B cells were
used (22). However, reconstitution of lethally irradiated
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recipient mice with the same infected progenitors consis-
tently resulted in the development of acute myeloid leukemia
(AML). AMLs were monoclonal or biclonal, each expressed
high levels of p85E2APbx1, and all grew in culture immedi-
ately after explant. Most were dependent on granulocyte-
macrophage colony-stimulating factor (GM-CSF) or inter-
leukin-3 (IL-3) for growth. These data prove that E2A-Pbxl
is a hematopoietic oncogene and reveal that its leukemic
potential is not restricted to the pre-B lineage.
MATERIALS AND METHODS
High-titer, helper-free stocks of retrovirus. The cDNA
encoding the 85-kDa form of E2A-Pbxl (11) was cloned into
the BclI site of the retroviral vector pGD (7). This vector was
transfected into the packaging cell line T-CRE, and a clone
(T-24L) expressing 5 x 105 infectious units/ml was identified
by screening viral RNA preparations from G418-resistant
colonies for maximal hybridization to a PBX1 probe.
Adoptive transfer (bone marrow reconstitution). Marrow
isolation, infection with retrovirus, and reconstitution of
lethally irradiated recipients were performed precisely as
described by Daley et al. (7). Briefly, 5 mg of 5-fluorouracil
(Sigma) was administered to donor BALB/c female mice by
tail vein injection. Six days later, marrow was collected from
femurs and tibias of 5-fluorouracil-treated mice. Progenitor
cells were purified by centrifugation of marrow on discon-
tinuous Ficoll-Paque (Pharmacia) gradients. Four million
purified marrow cells were cocultivated with 10 million
T-24L fibroblasts for 48 h in the presence of 10% WEHI-3B
supernatant as a source of IL-3 and 2 mg of Polybrene per
ml. IL-3 stimulates the growth of most multipotent progen-
itors and is essential to maintain their viability. The T-24L
fibroblasts were treated with 5,000 rads ofgamma irradiation
prior to use to prevent their continued replication and
prevent the subsequent injection of mice with transformed
NIH 3T3 fibroblasts. After 48 h of cocultivation, infected
donor marrow was collected by squirting the cells off the
monolayer and rinsing them twice in cold phosphate-buff-
352 KAMPS AND BALTIMORE
TRANSACTIVATION
4
E2A GENOMIC DNA
HYPOTHETICAL PBX1
GENOMIC STRUCTURE
E2A-Pbx PROTEINS
p85 E2A-Pbxl
mRNA
DNA BINDING
4 kb m-MEu Emu UHF EKE---m
* * *
TRANSACTIVATION
x
483 aa + 342 aa
I E2A
PBX1 EXONS IN
FUSION TRANSCRIPT
I I-_ _
LHEB
HOMEOBOX
HOMEOBOX
0 DOmmMA
k AAAA~~
mRNA ' AAAA
p77 E2A-Pbxl I E2A Ibx M
259 aa
FIG. 1. Depiction of the t(1;19) chromosomal translocation and its effects at the mRNA and protein levels. Exons from E2A encoding an
amino-terminal transactivation domain are fused with exons from PBX1 encoding a homeobox DNA-binding domain. At least two spliced
variants of the E2A-Pbxl fusion protein result from this DNA rearrangement. The larger one, designated p85E2APbx1, was used for our
experiments because it is the most abunda-nt form produced in pre-B ALL cells containing the t(1;19) translocation (11). aa, amino acids.
ered saline (PBS). Eight BALB/c mice were subjected twice,
at 4-h intervals, to 455 rads ofgamma irradiation to eliminate
endogenous hematopoiesis, and each was then reconstituted
with 2 x 106 E2A-Pbxl virus-infected marrow cells by tail
vein injection. Mice were maintained in microisolator cages
and were fed sterile food and acid water for 6 weeks prior to
reconstitution and forever thereafter.
Transfer of leukemic cells to secondary recipients. Second-
ary mice were subjected to a single dose of sublethal
radiation (450 rads). A total of 2 x 106 cells derived from
specified sources (see Table 2) in the primary leukemic mice
were injected into the tail vein in a total volume of 200 ,ul.
Mice were maintained in microisolator cages and fed normal
food and water.
Clonal analysis of tumors. Samples of genomic tumor DNA
were digested with EcoRI, which cuts between the E2A-
Pbxl and neomycin cDNAs in the retroviral vector and in
unique sites in the host DNA, thereby producing size frag-
ments that are diagnostic of a specific clone of cells. Di-
gested DNA was analyzed on Southern blots, using the
neomycin cDNA as a probe.
Cells and antisera. Leukemic cells from mouse AMLs
were grown in RPMI 1640 containing 20% Ham's F12
medium, 10% fetal bovine serum, 50 p,M 2-mercaptoethanol,
and 16 U of GM-CSF per ml (1% supernatant from a B16
melanoma cell line secreting recombinant GM-CSF) and
supplemented with glutamine, nonessential amino acids, and
antibiotics. LyD9 pre-B cells were grown in RPMI 1640
containing 10% fetal bovine serum, 50 ,uM 2-mercaptoetha-
nol, and 10% WEHI-3B supernatant as a source of IL-3.
Antibodies to Pbxl were raised in rabbits against a fusion
protein between glutathione S-transferase and Pbxl and
were affinity purified against the same recombinant fusion
protein as described by Kamps et al. (11).
Anti-Pbxl immunoblotting. Samples of tissue containing
leukemic cells were suspended in PBS (10 mM sodium
phosphate [pH 7.2], 150 mM NaCl) in a 1.5-ml Eppendorf
tube and dispersed by grinding with a Teflon pestle. Marrow
was ejected from isolated femurs by cutting off the ends of
the bone and forcing out the marrow with a stream of
medium from a 25-gauge needle. Cells were washed twice in
PBS, counted, and boiled in protein gel sample buffer at a
concentration of 5 x 107/ml. Total cellular proteins in 20 RI
of each sample were resolved by electrophoresis through
10% polyacrylamide gels and transferred to nitrocellulose.
E2A-Pbxl was stained by incubation of filters in affinity-
purified, polyclonal rabbit antibodies to Pbxl (10 ,g/ml)
followed by incubation in alkaline phosphatase-conjugated,
goat anti-rabbit immunoglobulins and reaction with nitroblue
tetrazolium and 5-bromo-4-chloro-3-indolylphosphate tolui-
dinium as described previously (11).
Immunofluorescence. Binding of rat monoclonal antibodies
to B220, Thy 1.2, and Mac-1 and of fluorescein isothiocy-
anate-conjugated goat anti-rat antibodies was performed on
live cells in PBS, after which the cells were fixed in
paraformaldehyde and analyzed by immunofluorescence.
RESULTS
E2A-Pbxl causes an AML-like disease in mice that is
accompanied by granulocytic sarcomas. Eight female
BALB/c mice, designated HF1 to HF8 (helper-free mice 1 to
8), were transplanted with bone marrow from donor male
mice that had been infected by a helper-free population of
virus encoding p85E2A-Pbxl. At 11 to 30 weeks posttrans-
plant, mice HF1 to HF7 became sick, as evidenced by
patchy fur, lethargy, hind limb paralysis, and enlarged
palpable spleens. When mice became critically ill, usually
within 7 days of exhibiting these symptoms, they were
sacrificed, and their diseases were analyzed (Table 1). The
control mouse was a nontransplanted littermate of the trans-
planted mice. Mouse HF8 was transplanted with E2A-Pbxl
virus-infected marrow, remained asymptomatic, and was
sacrificed together with the control mouse at the end of the
33-week study. By comparison with the control, each dis-
eased mouse exhibited an increased fraction of immature
blasts in marrow (from 30 to 95% of total nucleated cells
versus 10% in normal mice) (Fig. 2D and 2C; Table 1) and an
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TABLE 1. Characteristics of E2A-Pbxl disease in mice
Mouse' Survival Leukocyte count Hematocrit Marrow blast Spleen Granulocytic Other sites of tumor Hind limb(wk) (103/ml)b fraction (%)C (g) sarcoma (g)d involvement paralysise
Control 33 6 49 8 0.08
HF8 33 4 53 9 0.06
HF1 11 185 38 76 0.80 0.06 (IP) Liver +++
HF1.1 12 22 0.80
HF2 19 54 42 48 0.33 0.7 (IP) Ascites fluid, liver,
lung
HF2.1 37 40 0.50 2.9 (PS) Liver +++
HF3 21 33 22 86 0.60 1.0 (PS) +++
HF3.2 3 15 0.75 2.2 (PS) +++
HF4 21 15 16 95 0.66 Nodes
HF4.1 12 28 0.90
HF5 24 8 30 70 0.60 2.7 (IP-PS) Lung
HF5.1 12 47 1.60 Liver
HF6 29 11 50 30 0.20 1.4 (FM)
HF7 30 11 18 70 1.00 0.18 (PS) Liver
0.14 (IP)
a HF1.1 to HF4.1 were injected with marrow from leukemic mice HF1 to HF4, respectively, and HF5.1 was injected with spleen cells from leukemic mouse
HF5.
b Number of nonerythrocytes in whole blood at the time of sacrifice.
c Assessed after staining cytospins with Wright-Giemsa stain.
d Locations of masses: IP, intraperitoneal; PS, paraspinus; FM, femur.
I Absolute block of hind limb movement.
enlarged spleen (2.5- to 20-fold) (Fig. 2A and B; Table 1), and
most mice contained proliferating blasts in liver or lung. All
sick mice exhibited reduced hematocrits (packed erythro-
cyte volume) that paralleled the degree to which marrow was
replaced by tumor cells (Table 1) and contained an increase
in peripheral blood leukocytes (1.5- to 36-fold) due to large
numbers of myeloblasts and immature neutrophils. Immun-
ofluorescence analysis indicated that all proliferating blasts
were myeloid (positive for the myeloid surface antigen
Mac-1 and negative for the B- and pre-B-cell surface antigen
B220 and the T- and pre-T-cell surface antigen Thy 1.2; data
not shown). Clonal analysis based on unique retroviral
integration sites demonstrated that all cells comprising each
proliferative disorder were either monoclonal or biclonal and
contained, at most, two integrated proviruses (unique sites
designated A to L in Table 2; minor populations of distinct
clones are designated in parentheses).
Six of the seven mice contained solid masses of leukemic
cells, weighing up to 2.9 g, in nonhematopoietic tissue (Fig.
2B, G, I, K, and L), that were in two cases (HF3 and HF6)
composed of a unique cell clone (Table 2). These masses
appeared to be the mouse cognate of human granulocytic
sarcomas (also designated chloromas or myeloblastomas)
because they were composed, again, strictly of myeloid
cells. In humans, granulocytic sarcoma is a rare myeloid
malignancy, accompanying approximately 1% ofAMLs, and
most often associated with AML or the transition of chronic
myeloid leukemia (CML) or myelodysplastic syndrome
(MDS) to AML (16). The mouse granulocytic sarcomas
exhibited a wide variation in degree of differentiation (Table
2), as do their human counterparts (16). As in human AML
(16), they also grew in diverse locations in diseased mice,
including the peritoneal cavity and regions adjacent to the
spinal column (Table 1). Spinal cord compression resulting
from their growth is likely to be responsible for the hind limb
paralysis observed in mice HF1, HF2, and HF3 because
both intradural and epidural spinal compressions resulting
from granulocytic sarcomas have been reported to cause
paralysis in humans (10, 15). The mouse granulocytic sarco-
mas also mimicked their human counterparts by sometimes
arising before extensive hematopoietic progression of AML
(e.g., mouse HF6).
On the basis of a 30 to 95% abundance of myeloblasts in
marrow frequently accompanied by granulocytic sarcomas,
these proliferative disorders were diagnosed as AML rather
than CML or MDS. Expression of E2A-Pbxl in tumor tissue
was analyzed by Western immunoblotting with antibodies
against Pbxl. Tumor cells from marrow, spleen, liver, gran-
ulocytic sarcomas, and ascites fluid contained amounts of
p85E2A-Pbxl comparable to those present in the t(1;19)-
containing human pre-B ALL cell line 697 (a subset is
represented in Fig. 3A), strongly suggesting that retrovirus-
induced expression of p85E2A-15bx performs an essential role
in the genesis of these leukemias.
Consistent with the behavior ofAML in mice, E2A-Pbxl-
associated AML was transferred efficiently to secondary
recipients (Table 1); each AML that developed in a second-
ary recipient was derived from one of the original leukemic
donor clones (Table 2). (In Table 1, HF1.1 refers to the
secondary recipient of 2 x 106 cells from the primary
diseased mouse, HF1.)
E2A-Pbxl disease is marked by factor dependence and
blocked differentiation. Each AML exhibited variable de-
grees of differentiation in vivo. This variation was most
strongly demonstrated by analyzing granulocytic sarcomas
because these solid masses contain essentially only tumor
cells. The granulocytic sarcomas exhibited different degrees
of differentiation; some consisted almost solely of myelo-
blasts (Fig. 2K; Table 2), whereas others contained mostly
myelocytes and metamyelocytes (Fig. 21). Partial differenti-
ation of leukemic cells was also evident in the peripheral
blood of mouse HF1 (20-fold-elevated leukocyte count; Fig.
2E) and in the ascites fluid of mouse HF2 (Fig. 2F). Other
AMLs exhibited a phenotype indicative of a stronger block
in differentiation at the promyelocyte (HF4; Fig. 2J) or
myeloblast stage (HF3, HF5, and HF7; Fig. 2H, K, and L,
respectively).
Cell lines representing original AML clones from each
mouse (Table 2) were readily established by growth in
GM-CSF (final concentration, 16 U/ml). All clones main-
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FIG. 2. (A to L) Morphology of AML cells resulting from disease induced in mice by E2A-Pbxl. Seven of the eight reconstituted mice,
designated HF1 to HF7, developed AML, each of which was clonal or pauciclonal (Table 2) and all of which contained significant amounts
of p85E2A-Pbxl (Fig. 3). (A and B) Diseased mice at sacrifice. (A) Mouse HF1, exhibiting tumor nodules in the spleen and tumor growth (lighter
zones) in the liver (cells pictured in panels D to E); (B) mouse HF5, containing a large granulocytic sarcoma (white mass just below spleen;
see panel K). (C to L) Wright-Giemsa stains of cells from normal (C) and leukemic (D to L) tissues at the time of sacrifice. (C) Normal mouse
marrow, containing a large myeloblast (upper center) and cells exhibiting properties of normal neutrophil differentiation (a circular nucleus,
condensed chromatin, and transparent cytoplasm); (D) marrow from HF1, containing predominantly blasts with limited neutrophil
maturation; (E) Ficoll-purified blood cells from HF1; (F) ascites fluid from HF2, containing a large population of myelocytes and neutrophils
exhibiting abnormal chromatin condensation, and blue-staining cytoplasm; (G) granulocytic sarcoma from HF2, containing the same clone of
cells as represented in ascites fluid (F); (H) myeloblasts from HF3 spleen; (I) granulocytic sarcoma from HF3, representing a clone of
malignant cells different from those depicted in panel H; (J) HF4 spleen, exhibiting a promyelocytic phenotype; (K) granulocytic sarcoma
from HF5; (L) HF7 spleen, exhibiting a myeloblastic phenotype. Bottom panel, the myeloid differentiation pathway. Myeloid progenitors
remain mitotic until the myelocyte stage. Mouse myelocytes develop a distinctive "donut" morphology, which facilitates their easy
identification. As chromatin condenses, the cytoplasm becomes virtually transparent to staining.
tained their myeloid phenotype in culture (Mac-1 positive,
Thy 1.2 negative, B220 negative) with the exception of clone
G from mouse HF4, which also became strongly Thy 1.2
positive. Each line was tested for its dependence on GM-
CSF for growth. In the absence of GM-CSF, clones A, G,
and L continued to proliferate whereas clones D, E, F, and
J died (Fig. 4). These data suggest that one of the target cells
for transformation by E2A-Pbxl is a GM-CSF-dependent
myeloid progenitor. The results also demonstrated that
p85E2A-Pbx1 does not substitute fully for the viability or
growth-stimulatory functions of GM-CSF. Expression of
either p85E2A-Pbx or p77E2A-Pbxl in LyD9 pro-B cells (18)
also did not alter their IL-3 dependence, demonstrating that
the function of E2A-Pbxl is distinct from that of v-Abl or
Bcr-Abl, both of which abrogate IL-3 dependence (5, 6).
A major defect in each AML clone was its inability to
differentiate in response to GM-CSF. When cultured in 16 U
of GM-CSF per ml, a clone from each AML grew out as a
cell line. All cell lines except clone G consisted of myelo-
blasts, 1 to 20% of which resembled myelocytes or metamy-
elocytes (Fig. 2, bottom panel). In contrast to the behavior of
the AML cell lines, normal GM-CSF-responsive progenitors
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TABLE 2. Analysis of clonality and degree of differentiation of primary and secondary AMLs
% Maturing Integration site Site(s) in
Mouse Tissue neutrophilsa designation(s)b cell lineb
HF1 Blood 73 A, (B)
Spleen 47 A, (B) A
Liver 50 A, (B)
HF1.1 Spleen 21 A
HF2 Spleen 67 C
Granulocytic sarcoma 78 C, (D) D, (C)
Ascites fluid 89 C
HF2.1 Spleen 43 C
Granulocytic sarcoma 53 C
HF3 Spleen 7 E E
Granulocytic sarcoma 93 F E
HF3.1 Spleen 0.2 E
Granulocytic sarcoma 1 E
HF4 Spleen 2c G G
HF4.1 Spleen 2 G
HF5 Spleen 14 H
Granulocytic sarcoma 6 H, (I) H, (I)
HF5.1 Spleen 4 H
HF6 Marrow _d J J
Granulocytic sarcoma 33 K
HF7 Spleen 4 L L
Fraction of cells comprising the nonmitotic fraction of tumor cells (metamyelocytes, banded forms, and mature neutrophils; see Fig. 2C).
b Minor populations of distinct clones are indicated in parentheses.
c Of the 98% of immature cells, all of which were heavily granulated (Fig. 2J), 50% contained nuclei exhibiting the "donut" morphology.
d Normal myelopoiesis precluded an accurate determination of differentiation of the malignant clone.
isolated from marrow proliferate and undergo terminal dif-
ferentiation to neutrophils and macrophages within 4 weeks
of being cultured in 16 U of GM-CSF per ml. None of the
AML clones were induced to differentiate by the addition of
G-CSF to media containing GM-CSF, nor did G-CSF alone
substitute for GM-CSF or induce differentiation in GM-CSF-
independent clones.
After cultivation in GM-CSF-containing medium for 5
months, each AML maintained expression of E2A-Pbxl at
levels comparable to that found in the human pre-B ALL line
697 (Fig. 3C). Although cells from HF5 initially expressed
only p85E Pbxl (Fig. 3A, lanes 10 and 11), they expressed
both full-length p85E2APbx1 and a shorter Pbxl-containing
protein after cultivation in vitro for 4 months (Fig. 3C, lane 3).
It is possible that the mutation in this form of E2A-Pbxl
contains an activating carboxyl-terminal deletion similar to
that which enhances the transforming potential of p77El-Pb1
(11).
DISCUSSION
E2A-Pbxl-induced disease was diagnosed as AML on the
basis of its (i) myeloid immunologic and histologic pheno-
type, (ii) high fraction of marrow blasts, (iii) presentation
with granulocytic sarcoma, (iv) variable level of circulating
myeloid progenitors, (v) ease of transmission to secondary
recipients, and (vi) ease of establishment as GM-CSF-depen-
dent cell lines in culture. E2A-Pbxl disease was not diag-
nosed as CML or MDS. In humans, CML is consistently
accompanied by a large increase in the abundance of mature
and maturing neutrophils in the periphery. In three cases,
HF1, HF2, and HF3, E2A-Pbxl disease was accompanied
by substantial increases in circulating neutrophil progenitors
that typify CML; however, the rapidly rising leukocyte
count in these mice occurred coincident with the growth of
granulocytic sarcomas, a high marrow blast fraction, and
efficient transplantability of the leukemic clone in secondary
mice, arguing that the disease represented AML. In addi-
tion, some human AMLs, specifically the M2 subgroup
containing the t(8;21) translocation, exhibit substantial neu-
trophilic differentiation of circulating leukemic cells (1). The
transplantability of E2A-Pbxl disease distinguishes it from
the CML-like diseases induced by retrovirus-mediated ex-
pression of p210BCrAbl or gpl20v-Fms, which are character-
ized by a dramatic increase in mature, circulating neutro-
phils and which are nontransplantable (8, 24). E2A-Pbxl
disease was distinct from MDS, which in humans is charac-
terized by an enlarged spleen in only 20% of cases, a
suppressed leukocyte count, and less than 30% blasts in
marrow, with cells exhibiting morphologic evidence of ab-
normal myeloid cell development. In addition, MDS itself is
not accompanied by the growth of granulocytic sarcomas,
which are Observed in five AML-associated contexts: (i)
precedingAML in apparently normal individuals, (ii) accom-
panying AML, (iii) accompanying blast crisis in CML, (iv)
accompanying conversion of MDS to AML, or (v) fully
independent of other detectable AML, CML, or MDS (4, 13,
16, 21, 24-26). Finally, it is possible that E2A-Pbxl-associ-
ated AMLs were preceded either by MDS or by a very brief
CML-like phase.
Expression of E2A-Pbxl alone appears insufficient to
produce AML. Because E2A-Pbxl itself did not induce
factor independence, the lymphokine-independent growth of
clones A, G, and L indicates that secondary mutations
abrogating factor dependence have probably occurred.
These mutations may complement the function of E2A-Pbxl
in producing overt AML in these cases. The hypothesis for
secondary mutation is also supported by analysis of mouse
HF8, which remained asymptomatic 8 months posttrans-
plantation even though its marrow and spleen expressed
moderate amounts of p85E2A-Pbxl (Fig. 3B; marrow appeared
normal as assessed from Wright-Giemsa stains). The clonal-
ity of each leukemia also suggests that an additional muta-
tion(s) might complement E2A-Pbxl expression to produce
dominant outgrowth of a single cell. Secondary mutations
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FIG. 3. Immunoblot analysis of E2A-Pbxl proteins in mouse
AMLs. Samples of leukemic cells were isolated from tissue, rinsed
in PBS, and subjected to anti-Pbxl immunoblotting as described in
Materials and Methods. Lanes 697 contain extracts from human 697
pre-B cells, which contain the t(1;19) translocation; lanes Nalm
contain extracts from human Nalm-6 pre-B cells, which do not
contain t(1;19). p85 and p77 indicate the positions of native
p85E2A-Pbxl and p77E2A-Pbxl from 697 cells. (A) Lanes: 1 to 4, HF1
marrow, spleen, Ficoll-purified peripheral blood leukocytes, and
liver, respectively; 5 to 7, HF7 mass, spleen, and marrow, respec-
tively; 8 and 9, HF6 mass and spleen, respectively; 10 and 11, HF5
mass and spleen, respectively. (B) Immunoblot performed on tis-
sues from a nontransplanted mouse and from a mouse that was
transplanted with marrow infected by the p85E2APbxl virus yet
remained asymptomatic after 8 months (HF8). Lanes: 1, normal
marrow; 2, HF8 marrow; 3, normal spleen; 4, HF8 spleen. (C)
Anti-Pbxl immunoblot containing extracts from cell lines L, J, H,
G, E, D, and A (lanes 1 to 7, respectively), as defined in Table 2.
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might account for the wide variance in differentiation exhib-
ited by each AML.
One mechanism for the relatively long latency of disease
in transplanted mice might be the activation of endogenous
helper virus or recombination of the E2A-Pbxl retroviral
vector with an endogenous host provirus to generate a
myelotrophic helper virus. If this were to happen, one might
argue that the AMLs observed in this model were induced by
helper virus alone. Two experiments strongly discount this
possibility. First, if any of the mouse AMLs contained
helper virus, they should produce virions containing the
recombinant E2A-Pbxl genomic RNA that could confer
G418 resistance upon infected NIH 3T3 cells. Samples (6 ml)
of culture supernatants from clones A, E, G, H, J, and L
were tested for this activity, and none were positive. Sec-
ond, we have now demonstrated directly that helper-free
virus encoding p85E2A-Pbxl will reproducibly immortalize
primary marrow GM-CSF-dependent progenitors within 4
weeks of infection of primary marrow only when these cells
are cultivated in the presence of GM-CSF, whereas infection
by an equivalent titer of the parental neomycin virus, or
helper virus alone, does not result in the outgrowth of
myeloblasts (10a). These results support the suggestion that
p85E2A-Pbxl is essential for the genesis ofAML in this mouse
model and demonstrate that insertional mutagenesis by a
helper provirus is an unlikely mechanism for generating
complementary oncogenic mutations.
By what molecular mechanisms does p85E2A-Pbxl cause
AML? One mechanism would be competition with other Pbx
homeobox proteins for a single specific DNA recognition
sequence that regulates transcription of a family of Pbx-
responsive genes. Three PBX genes (PBX1 to PBX3), en-
coding a distinct family of homeobox proteins, have been
sequenced thus far (14; our unpublished observations) and
are widely expressed in both fetal and adult tissue (11, 14).
The proteins that they encode contain almost identical
homeoboxes, exhibit extensive amino acid identity in non-
homeobox sequences, and diverge significantly in only small
amino-terminal and carboxyl-terminal domains. Therefore,
A D E F G H J L
AML clone
FIG. 4. Growth factor dependence of cell lines derived from AMLs. Approximately 100,000 cells from cell lines representing each AML
(Table 2) were grown in the presence (open squares) or absence (filled squares) of GM-CSF for 5 days. The vertical axis represents cell
populations in thousands. Cell clones were derived from each mouse as follows: clone A (HF1), clone D (HF2), clone E (HF3 spleen), clone
F (HF3 mass), clone G (HF4), clone H (HF5), clone J (HF6), and clone L (HF7).
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it is possible that all Pbx proteins bind the same DNA
sequence motif and that a minimum threshold of p85E2A-Pbx1
is required to compete with normal Pbx proteins and inter-
fere with their regulation of Pbx-responsive genes. Alterna-
tively, overexpression of p85E2A-Pbxl might titrate out an
E2A- or Pbx-binding protein that is required for normal
differentiation. Answers to these mechanistic questions are
the subject of current investigations aimed at determining
how the structural and biochemical properties of E2A-Pbxl
govern its transforming abilities.
The association of p85E2A-Pbxl with AML in mice raises
the possibility that Pbxl as well as Pbx2 and Pbx3 has
oncogenic roles in other malignancies. However, the lack of
pre-B disease in mice engrafted with p85E2A Pbxl-expressing
marrow is puzzling. The dominant AML phenotype might
arise if the population of myeloid progenitors susceptible to
transformation by p85E2A-Pbxl vastly outnumbered that of
B-lymphoid progenitors or if the transforming function of
E2A-Pbxl is more pronounced in myeloid progenitors than it
is in B-lymphoid progenitors. It is also possible that the
correct pre-B target cell is not efficiently infected when
marrow is cultured with virus-producing cells prior to intro-
duction into recipients; however, because experiments using
the same retroviral vector encoding p2l0Bcr-Abl led to pre-B
ALL in some mice (7), we would argue that expression of
p85E2A-Pbxl does occur at least in this pre-B-cell progenitor.
Alternatively, the need for mutation of a second gene, such
as N-ras, which is activated in a low frequency of childhood
ALLs and AMLs (2, 20), might occur more frequently in the
myeloid lineage than it does in the lymphoid lineage in mice.
Finally, marrow from 6-week-old mice may not contain a
target cell equivalent to that which undergoes the t(1;19)
chromosomal translocation in the generation of pre-B ALL
in humans. However, regardless of the reasons that account
for the absence of pre-B-cell disease in this mouse model, we
postulate that the transforming function of E2A-Pbxl in
human pre-B ALL is likely to parallel its transforming
function in mouse AML.
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